This Article Order Full text via Infotrieve Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Komiya, T. Articles by Mizuno, Y. Search for Related Content PubMed PubMed Citation Articles by Komiya, T. Articles by Mizuno, Y. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID Medline Plus Health Information Transient Ischemic Attack

Stroke, Vol 25, 2337-2342, Copyright © 1994 by American Heart Association

ARTICLES

Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Assessment by platelet aggregation testing

T Komiya, M Kudo, T Urabe and Y Mizuno
Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.

BACKGROUND AND PURPOSE: Antiplatelet therapy is currently one of the methods for preventing transient ischemic attacks and cerebral thrombosis. Because antiplatelet agents are generally administered on a long-term basis, patient compliance is an important factor. The purpose of this study was to determine the compliance of patients during antiplatelet therapy by testing platelet aggregation. METHODS: To establish the conditions for measuring platelet aggregation, the platelet aggregation test was performed in patients taking 81 mg/d aspirin or 200 mg/d ticlopidine at the following final concentrations of aggregation-inducing agents: 0.5, 1, 2, and 4 mumol/L ADP and 0.5 and 2 micrograms/mL collagen. The optimum measurement conditions for assessing patient compliance were determined. Under the conditions determined in the first study, platelet aggregation was assessed, and the effects of treatment were studied in 159 outpatients and 79 inpatients undergoing antiplatelet therapy. If the antiplatelet effect was insufficient, compliance was checked by interview. RESULTS: The agents used and the final concentrations found to be optimum for assessing platelet aggregation were 2 micrograms/mL collagen for patients taking aspirin 81 mg/day and 2 mumol/L ADP for patients taking ticlopidine 200 mg/d. In 17 (10%) of the 159 outpatients, platelet aggregation was not adequately reduced because of noncompliance with their antiplatelet therapy. CONCLUSIONS: This study indicated that monitoring of compliance is important for outpatients on antiplatelet therapy. It is best if platelet aggregation can be checked, but when this is impossible it is necessary to assess compliance periodically and provide patient guidance.

This article has been cited by other articles:

				S. E. Ramsay, R. W. Morris, O. Papacosta, L. T. Lennon, M. C. Thomas, and P. H. Whincup Secondary prevention of coronary heart disease in older British men: extent of inequalities before and after implementation of the National Service Framework J. Public Health Med., December 1, 2005; 27(4): 338 - 343. [Abstract] [Full Text] [PDF]

				I. Vucenik and J. J. Podczasy Whole Blood Lumiaggregation: Evaluation of Reagents Clinical and Applied Thrombosis/Hemostasis, October 1, 1998; 4(4): 253 - 256. [Abstract] [PDF]

				S. White and S. H. Y. Wong Standards of laboratory practice: analgesic drug monitoring Clin. Chem., May 1, 1998; 44(5): 1110 - 1123. [Abstract] [Full Text] [PDF]

				C. Patrono and G. J. Roth Aspirin in Ischemic Cerebrovascular Disease : How Strong Is the Case for a Different Dosing Regimen? Stroke, April 1, 1996; 27(4): 756 - 760. [Abstract] [Full Text]